RecruitingNCT05014165

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

Sponsor

Children's Oncology Group

Enrollment

300 participants

Start Date

Aug 25, 2021

Study Type

OBSERVATIONAL

Conditions

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia

Summary

A comprehensive mechanistic and epidemiological study to obtain banked cord blood samples from consecutive childhood leukemia patients enrolled in the COG Project:EveryChild (APEC14B1) study. Will attempt to backtrack the initiating genomic alteration identified in the matched diagnostic leukemia sample and molecularly characterize pre-leukemic cells. The ultimate goal of this research is to pinpoint the cell of origin of leukemogenic alterations formed in utero, elucidating the etiology of these initiating mutations (as opposed to frank leukemia), and devising a test for circulating pre-leukemia that can be applied on a population-wide basis.

Eligibility

Max Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This study investigates whether the genetic mutations that cause childhood leukemia (blood cancer) were already present at birth by looking at stored cord blood samples. This research could reveal how early leukemia actually starts developing. **You may be eligible if...** - You have been diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) - Pre-treatment tissue samples from your original diagnosis are available at a biorepository - You are enrolled in a related cancer research registry (APEC14B1) and consented to future contact - Your cord blood was stored at birth and remains available - A parent or guardian has agreed to participate on your behalf (if applicable) **You may NOT be eligible if...** - Your stored diagnostic samples are unavailable or insufficient - You did not have cord blood stored at birth - You or your guardian did not consent to future contact in the registry Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCord blood Sample Collection

Obtain banked cord blood samples from consecutive childhood leukemia patients

OTHERCase identification and recruitment

Cases meeting eligibility and who have given consent through APEC14B1 for future contact for non-therapeutic studies

OTHERQuestionnaire Administration

The family will be given an option to complete questionnaire on paper, online, or over the telephone.

Locations(1)

University of Minnesota/Masonic Cancer Center

Minneapolis, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05014165

Related Trials

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649220 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393177 locations

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406220 locations

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

NCT0495389721 locations